Navigation Links
Hurel Corporation Announces Grant Program Based On Its 3-D Tissue Construct Technologies, Readies Call For Research Proposals From Academic Community

NORTH BRUNSWICK, N.J., Sept. 26, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a leading developer of cell-based tissue constructs and microfluidic assay platforms that can improve the speed and accuracy of pre-clinical prediction in drug development, today announced an ambitious new research grant program to spur innovation in the use of its cell-based models in pharmaceutical and industrial toxicological research.  The company said it is prepared to commit in aggregate up to $150,000 under the grant program, and that it intends to invite qualified academic research scientists to submit funding proposals for projects that will seek to trailblaze new uses and applications for Hurel's high-functioning, long enduring hepatic tissue cultures.

Hurel focuses on the production of 3-dimensional tissue cultures that simulate and predict the in vivo function of the liver and other organs.  The Company recently launched its Hurelhuman™, Hureldog™, and Hurelrat™ product lines, which are created from the primary (i.e., actual) liver cells of the respective species.  Hureldog™ is the first characterized, 3-D tissue culture product based on primary liver cells from the canine species.

"Over the past three decades, my colleagues and I have developed and tested several different hepatic tissue constructs, many of which are utilized by researchers today, such as gel-overlay hepatocyte cultures and micropatterned co-cultures," said Martin Yarmush, MD, PhD, Hurel's Chief Scientific Adviser.  "In the evolution of these hepatic models, the Hurel® co-culture is the first that we deliberately engineered for use in industrial scientific research, where manufacturing efficiency, ability to replicate results, and ease of use in the lab are virtues of an importance equal to that of the cellular competency of the model itself. With such a 'workhorse' platform in hand, we are intensely curious to see how our academic colleagues, drawing on their knowledge and their scientific imaginations, may seek to probe its capabilities and push the envelope of its potential applications."

The formal Call for Proposals document is currently being finalized and Hurel anticipates releasing it in late October, 2013.  The Call for Proposals will be available through Hurel's website --  The anticipated application deadline is January 30, 2014 and the Company expects that grant awards will be announced by March 15, 2014.  Hurel's Scientific Advisory Board ("SAB") will serve as the grant review committee.  Hurel's SAB includes, among others, Leslie Z. Benet, Ph.D., Professor of Pharmaceutical Sciences at the University of California, San Francisco; Martin Yarmush, M.D., Ph.D., Professor of Biomedical Engineering at Rutgers University and Head of the Center for Engineering in Medicine at Massachusetts General Hospital, Boston; and James MacDonald, Ph.D., DABT, formerly the Executive Vice President for Pre-Clinical Discovery, Schering-Plough Research Institute.

About Hurel

Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms that are used by major pharmaceutical research organizations  in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products.  More information about Hurel can be found at .


SOURCE Hurel Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
3. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
4. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
5. Neogen Corporation Announces 2nd Quarter Results Conference Call
6. Luminex Corporation to Present at JP Morgan Healthcare Conference
7. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
8. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
9. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):